Health Care [ 9/12 ] | Biotechnology [ 58/73 ]
NASDAQ | Common Stock
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases.
The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept.
Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 25 | 3.62 Increased by +399.17% | 0.01 Increased by +48.17 K% |
| Feb 26, 25 | -1.14 Increased by +14.93% | -0.43 Decreased by -166.98% |
| Nov 4, 24 | -1.41 Decreased by -6.02% | -1.28 Decreased by -10.16% |
| Aug 6, 24 | -1.25 Increased by +1.57% | -1.23 Decreased by -1.63% |
| May 8, 24 | -1.21 Increased by +3.97% | -1.35 Increased by +10.37% |
| Feb 28, 24 | -1.34 Decreased by -22.94% | -1.37 Increased by +2.19% |
| Nov 6, 23 | -1.33 Decreased by -44.57% | -1.35 Increased by +1.48% |
| Aug 7, 23 | -1.27 Decreased by -12.39% | -1.34 Increased by +5.22% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 211.25 M Increased by +254.41 K% | 148.45 M Increased by +444.32% | Increased by +70.27% Increased by +100.14% |
| Dec 31, 24 | 3.04 M Increased by +2.03 K% | -46.03 M Decreased by -14.37% | Decreased by -1.51 K% Increased by +94.62% |
| Sep 30, 24 | 388.00 K Increased by +4.75 K% | -52.96 M Decreased by -34.27% | Decreased by -13.65 K% Increased by +97.23% |
| Jun 30, 24 | 37.00 K Increased by +N/A% | -45.26 M Decreased by -20.67% | Decreased by -122.32 K% Decreased by N/A% |
| Mar 31, 24 | 83.00 K Increased by +N/A% | -43.11 M Decreased by -31.69% | Decreased by -51.94 K% Decreased by N/A% |
| Dec 31, 23 | 143.00 K Increased by +N/A% | -40.24 M Decreased by -35.41% | Decreased by -28.14 K% Decreased by N/A% |
| Sep 30, 23 | 8.00 K Increased by +N/A% | -39.44 M Decreased by -107.12% | Decreased by -493.00 K% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -37.51 M Decreased by -57.56% | Decreased by N/A% Decreased by N/A% |